H Lundbeck A/S (LUN.CO) Osake Kurssi
H Lundbeck A/S Kurssi
Liikevaihto on kasvanut 5,2 % vuodessa viimeisten 19 vuoden aikana 24,35 Mrd. DKK:een. Osakekohtainen tulos on kasvanut 2,4 % vuodessa viimeisten 19 vuoden aikana. H Lundbeck A/Sn nettomarginaali on nyt 13,1 %, noussut 8,1 %:sta muutama vuosi sitten. H Lundbeck A/Sn osinkotuotto on tällä hetkellä noin 3,66 %. Jakosuhde on noin 21 % tuloksesta. Analyytikoiden mediaanitavoitehinta on 204,00 DKK, eli yli nykyhintaa 273,6 %. 20 analyytikosta 9 suosittaa ostoa — kokonaiskonsensus on Pidä.
H Lundbeck A/S osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
H Lundbeck A/S liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset H Lundbeck A/S -osakkeesta
H Lundbeck A/S operates under a pharmaceutical business model. This Danish company specializes in the research, development, production, marketing, and sale of drugs used in the treatment of various brain disorders. With a focus on psychiatric and neurological disorders, Lundbeck A/S aims to improve the lives of patients suffering from conditions such as depression, anxiety, schizophrenia, Parkinson's disease, and Alzheimer's disease. By constantly investing in research and innovation, Lundbeck A/S strives to deliver effective and safe medications that positively impact the well-being of patients worldwide.
H Lundbeck A/S is primarily active in the pharmaceutical industry.
The main competitors of H Lundbeck A/S in the market include pharmaceutical companies such as AstraZeneca, Novartis, and Pfizer. These companies also operate in the pharmaceutical industry and offer a range of products and therapies in the same therapeutic areas as Lundbeck, including neurology and psychiatry. Through their research and development efforts, marketing strategies, and product portfolios, these competitors strive to gain market share and serve patients with similar medical needs. Lundbeck's positioning in the market involves staying competitive against these major players by focusing on innovation, differentiation, and strategic collaborations to offer unique treatment options and deliver value to patients and healthcare providers.
H Lundbeck A/S is a Danish pharmaceutical company that specializes in developing and manufacturing drugs for the treatment of brain disorders. Founded in 1915 by Hans Lundbeck, the company has a long history of innovation in the field of neuroscience. Over the years, Lundbeck has built a strong reputation for its research and development efforts, particularly in the areas of depression, anxiety, and schizophrenia. Today, it is a global leader in the production of psychiatric and neurological medications. With its commitment to improving the lives of patients suffering from brain disorders, H Lundbeck A/S continues to make significant contributions to the field of pharmaceuticals.
H Lundbeck A/S has achieved several significant milestones in its history. The company, founded in 1915, has established itself as a leading pharmaceutical company in the field of brain diseases. Lundbeck is known for its research and development efforts, resulting in the successful launch of innovative medications. Notable milestones include the launch of Lexapro®, an antidepressant that became one of the top-selling drugs worldwide. Lundbeck also obtained FDA approval for Sabril®, a medication used in the treatment of epilepsy. The company continues to focus on researching and developing new treatments for brain disorders, aiming to improve the quality of life for patients globally.
H Lundbeck A/S is primarily present in multiple countries and regions globally. Some of the key markets where the company operates include the United States, Europe, Japan, China, and Brazil. With a strong presence in these regions, H Lundbeck A/S serves a broad customer base and caters to the needs of patients and healthcare professionals in diverse markets.
H Lundbeck A/S represents a strong commitment to improving the lives of people with brain diseases. With a focus on neuroscience, the company is dedicated to discovering and developing innovative treatments for conditions such as depression, schizophrenia, and Alzheimer's disease. Lundbeck values scientific excellence, integrity, and patient-centric research, ensuring that their products meet the highest standards of quality and safety. As a global pharmaceutical company, Lundbeck embraces a corporate philosophy that emphasizes collaboration, diversity, and sustainability. Through their ongoing efforts, Lundbeck strives to make a meaningful impact on the well-being of individuals affected by neurological and psychiatric disorders.
Analyytikot asettavat tällä hetkellä H Lundbeck A/S-osakkeelle keskimääräisen tavoitehinnan 204,75 DKK (mediaani: 204,00 DKK), mikä merkitsee +275,0 % viimeisimpään hintaan verrattuna. Konsensus perustuu 20 analyytikkoarvioon.
20 analyytikkoa arvioi tällä hetkellä H Lundbeck A/S-osaketta: 9 suosittaa ostoa, 9 pitoa ja 2 myyntiä. Vuodelle 2026 analyytikot odottavat H Lundbeck A/S-yhtiöltä 23,61 Mrd. DKK liikevaihtoa ja 7,23 DKK osakekohtaista tulosta.
Nykyisellä valuuttakurssilla H Lundbeck A/S-osake noteerataan hintaan 7,31 EUR (54,60 DKK).
H Lundbeck A/S-osake (LUN.CO) on listattuna 1 pörssissä, muun muassa: Kopenhagen (LUN.CO).
Lundbeck A/S is a Danish company specializing in the research, development, manufacturing, and marketing of drugs for the treatment of psychiatric and neurological disorders. The company operates in over 50 countries worldwide and employs roughly 6,000 employees. Lundbeck's core business includes four therapeutic areas: 1. Depression: Lundbeck offers a range of antidepressants for the treatment of depression and other mood disorders. Some of the most well-known products include Cipramil, Escitalopram, Sertraline, and Vortioxetine. 2. Schizophrenia: The company also provides medications for the treatment of schizophrenia, such as Aripiprazole, which is used to control hallucinations and delusions. 3. Alzheimer's disease: Lundbeck specializes in the development of drugs for Alzheimer's disease and offers products like Memantine and Ebixa, which reduce the symptoms of the disease. 4. Parkinson's disease: The company has also developed medications for the treatment of Parkinson's disease, such as Ajovy and Onzetra, which are used to relieve movement disorders and tremors. Lundbeck is also active in other areas, such as the therapy of anxiety disorders, sleep disorders, and epilepsy. The company is closely involved in research and development of new therapies to meet the medical needs of patients. Lundbeck's business model is based on collaboration with doctors, hospitals, and other healthcare providers to ensure that the right patients have access to the right therapies. The company also heavily invests in research and development to develop new drugs that meet the needs of patients and healthcare providers. The company has also established partnerships with other companies and institutions to focus on the research of new medications. For example, in 2018, Lundbeck partnered with Otsuka Pharmaceutical Co., Ltd. to jointly research and develop new drugs for psychiatric disorders. Lundbeck is also committed to increasing the availability of its products worldwide to facilitate access to medical therapies. The company has offices in North and South America, Europe, Asia, and Africa. In summary, Lundbeck is a leading company in the field of mental health, specializing in the research, development, manufacturing, and marketing of drugs for the treatment of psychiatric and neurological disorders. The company heavily invests in research and development to continuously develop new therapies that meet the needs of patients and healthcare providers. Lundbeck collaborates closely with other companies and institutions to increase the availability of therapies worldwide and facilitate access to medical care.
odotettu liikevaihto H Lundbeck A/S on 23,61 Mrd. DKK. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto H Lundbeck A/S on 7,17 Mrd. DKK. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
H Lundbeck A/S:n hinta-voitto-suhde (P/E) on tällä hetkellä 7,55. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan H Lundbeck A/S-osakkeen arvostusta.
H Lundbeck A/S:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,29. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii H Lundbeck A/S-osakkeen arvostuskennuslukuna.
H Lundbeck A/S:n Eulpool-laatuscore on 5/10.
H Lundbeck A/S:n ISIN on DK0010287234. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
H Lundbeck A/S:n WKN on 922351. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
H Lundbeck A/S:n ticker on LUN.CO. Tämä pörssinoteeraus käytetään H Lundbeck A/S-osakkeiden kauppaan pörssissä.
H Lundbeck A/S osake
H Lundbeck A/S vertaisryhmä
H Lundbeck A/S Ticker
Kaikki tunnusluvut ja syvällinen analyysi H Lundbeck A/S:sta
Meidän osakeanalyysimme H Lundbeck A/S-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut H Lundbeck A/S:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: